MedTrace Logo

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

NCT06322108 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-05-08

No results posted yet for this study

Summary

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.

Conditions

Interventions

DRUG

Botensilimab + Balstilimab

Botensilimab is a fragment crystallizable (Fc)-engineered human immunoglobulin G1 (IgG1) monoclonal antibody that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). Balstilimab is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1).

Sponsors & Collaborators

  • Agenus Inc.

    collaborator INDUSTRY

  • Immune Oncology Research Institute

    lead OTHER

Principal Investigators

  • Gevorg Tamamyan, MD, PhD, DSc · Immune Oncology Research Institute

  • Samvel Bardakhchyan, MD, PhD · Immune Oncology Research Institute

  • Samvel Bardakhchyan, MD, PhD · Immune Oncology Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2030-04-30
Completion
2030-04-30
FDA Drug
Yes

Countries

  • Armenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06322108 on ClinicalTrials.gov